MCP-1-induced protein attenuates post-infarct cardiac remodeling and dysfunction through mitigating NF-κB activation and suppressing inflammation-associated microRNA expression

Basic Research in Cardiology

Volumn 110, Issue 3, 2015, Pages

  Niu, Jianli ^a   Jin, Zhuqing ^b   Kim, Hyunbae ^a   Kolattukudy, Pappachan E ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Left ventricular remodeling; MCP 1 induced protein; Myocardial infarction

Indexed keywords

CASPASE 3; CASPASE 7; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MCP 1 INDUCED PROTEIN; MICRORNA; MICRORNA 126; MICRORNA 146A; MICRORNA 155; MICRORNA 199A; UNCLASSIFIED DRUG; RIBONUCLEASE; ZC3H12A PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDITIS; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCAR FORMATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; MYOCARDIAL INFARCTION; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEASES; SIGNAL TRANSDUCTION; TRANSFECTION; VENTRICULAR REMODELING;

EID: 84930958872     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-015-0483-8     Document Type: Article

References (59)

1. Arslan F, de Kleijn DP, Pasterkamp G (2011) Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 8:292–300. doi:10.1038/nrcardio.2011.38
2. Baer C, Squadrito ML, Iruela-Arispe ML, De Palma M (2013) Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Exp Cell Res 319:1626–1634. doi:10.1016/j.yexcr.2013.03.026
3. Baumgarten G, Kim SC, Stapel H, Vervölgyi V, Bittig A, Hoeft A, Meyer R, Grohé C, Knuefermann P (2006) Myocardial injury modulates the innate immune system and changes myocardial sensitivity. Basic Res Cardiol 101:427–435. doi:10.1007/s00395-006-0597-0
4. Blömer N, Pachel C, Hofmann U, Nordbeck P, Bauer W, Mathes D, Frey A, Bayer B, Vogel B, Ertl G, Bauersachs J, Frantz S (2013) 5-Lipoxygenase facilitates healing after myocardial infarction. Basic Res Cardiol 108:367. doi:10.1007/s00395-013-0367-8
5. Boldin MP, Baltimore D (2012) MicroRNAs, new effectors and regulators of NF-κB. Immunol Rev 246:205–220. doi:10.1038/ni.f.209
6. Chen J, Chen ZJ (2013) Regulation of NF-κB by ubiquitination. Curr Opin Immunol 25:4–12. doi:10.1016/j.coi.2012.12.005
7. Chen W, Saxena A, Li N, Sun J, Gupta A, Lee DW, Tian Q, Dobaczewski M, Frangogiannis NG (2012) Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts. Arterioscler Thromb Vasc Biol 32:2598–2608. doi:10.1161/ATVBAHA.112.300310
8. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek M, van Leeuwen R, Gijbels MJ, Wijnands E, Biessen EA, De Winther MP, Stassen FR, Carmeliet P, Kauppinen S, Schroen B, Heymans S (2012) MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 111:415–425. doi:10.1161/CIRCRESAHA.112.267443
9. Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, Frede S, Hartung T, Vinten-Johansen J, Youker KA, Entman ML, Erbel R, Heusch G (2002) Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 34:51–62. doi:10.1006/jmcc.2001.1489
10. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55–62. doi:10.1172/JCI8768
11. Duerr GD, Heinemann JC, Suchan G, Kolobara E, Wenzel D, Geisen C, Matthey M, Passe-Tietjen K, Mahmud W, Ghanem A, Tiemann K, Alferink J, Burgdorf S, Buchalla R, Zimmer A, Lutz B, Welz A, Fleischmann BK, Dewald O (2014) The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res Cardiol 109:425. doi:10.1007/s00395-014-0425-x
12. Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, Hochhauser E (2010) Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 48:1236–1244. doi:10.1016/j.yjmcc.2010.02.020
13. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O’Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP, Taylor CT (2011) An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 186:1091–1096. doi:10.4049/jimmunol.1002256
14. Frangogiannis NG (2014) The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol 63:185–195. doi:10.1038/nrcardio.2014.28
15. Fujiu K, Nagai R (2013) Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. Basic Res Cardiol 108:357. doi:10.1007/s00395-013-0357-x
16. Grabellus F, Levkau B, Sokoll A, Welp H, Schmid C, Deng MC, Takeda A, Breithardt G, Baba HA (2002) Reversible activation of nuclear factor-κB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res 53:124–130. doi:10.1016/S0008-6363(01)00433-3
17. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD (2011) Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 89:129–138. doi:10.1093/cvr/cvq274
18. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. doi:10.1016/S0140-6736(14)60107-0
19. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B (2013) Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:1420–1432. doi:10.1161/CIRCULATIONAHA.112.001357
20. Hofmann U, Frantz S (2013) How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol 108:356. doi:10.1007/s00395-013-0356-y
21. Hughes BG, Schulz R (2014) Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol 109:424. doi:10.1007/s00395-014-0424-y
22. Kain V, Prabhu SD, Halade GV (2014) Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109:444. doi:10.1007/s00395-014-0444-7
23. Kaucsár T, Bodor C, Godó M, Szalay C, Révész C, Németh Z, Mózes M, Szénási G, Rosivall L, Sőti C, Hamar P (2014) LPS-induced delayed preconditioning is mediated by Hsp90 and involves the heat shock response in mouse kidney. PLoS ONE 9:e92004. doi:10.1371/journal.pone.0092004
24. Kleinbongard P, Schulz R, Heusch G (2011) TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev 16:49–69. doi:10.1007/s10741-010-9180-8
25. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC (2007) Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115:1885–1894. doi:10.1161/CIRCULATIONAHA.106.656835
26. Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE, Fu M (2010) MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J Exp Med 207:2959–2973. doi:10.1084/jem.20092641
27. Liang J, Wang J, Saad Y, Warble L, Becerra E, Kolattukudy PE (2011) Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines. J Neuroinflammation 8:182–192. doi:10.1186/1742-2094-8-182
28. Lin L, Knowlton AA (2014) Innate immunity and cardiomyocytes in ischemic heart disease. Life Sci 100:1–8. doi:10.1016/j.lfs.2014.01.062
29. Maier HJ, Schips TG, Wietelmann A, Krüger M, Brunner C, Sauter M, Klingel K, Böttger T, Braun T, Wirth T (2012) Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109:11794–11799. doi:10.1073/pnas.1116584109
30. Mann DL (2011) The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108:1133–1145. doi:10.1161/CIRCRESAHA.110.226936
31. Martire A, Fernandez B, Buehler A, Strohm C, Schaper J, Zimmermann R, Kolattukudy PE, Schaper W (2003) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation. Cardiovasc Res 57:523–534. doi:10.1016/S0008-6363(02)00697-1
32. Maskrey BH, Megson IL, Whitfield PD, Rossi AG (2011) Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler Thromb Vasc Biol 31:1001–1006. doi:10.1161/ATVBAHA.110.213850
33. Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, Satoh T, Kato H, Tsujimura T, Nakamura H, Akira S (2009) Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458:1185–1190. doi:10.1038/nature07924
34. Merry HE, Wolf PS, Fitzsullivan E, Keech JC, Mulligan MS (2010) Lipopolysaccharide pre-conditioning is protective in lung ischemia-reperfusion injury. J Heart Lung Transplant 29:471–478. doi:10.1016/j.healun.2009.11.005
35. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U (2006) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99:891–899. doi:10.1161/01.RES.0000246113.82111.2d
36. Müller J, Gorressen S, Grandoch M, Feldmann K, Kretschmer I, Lehr S, Ding Z, Schmitt JP, Schrader J, Garbers C, Heusch G, Kelm M, Scheller J, Fischer JW (2014) Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction. Basic Res Cardiol 109:440. doi:10.1007/s00395-014-0440-y
37. Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and post-myocardial infarction remodeling. Circ Res 94:1543–1553. doi:10.1161/01.RES.0000130526.20854.fa
38. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolattukudy PE (2006) Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J Mol Cell Cardiol 40:810–820. doi:10.1016/j.yjmcc.2006.03.010
39. Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE (2008) Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 283:14542–14551. doi:10.1074/jbc.M802139200
40. Niu J, Gilliland MG, Jin Z, Kolattukudy PE, Hoffman WH (2014) MCP-1and IL-1β expression in the myocardia of two young patients with Type 1 diabetes mellitus and fatal diabetic ketoacidosis. Exp Mol Pathol 96:71–79. doi:10.1016/j.yexmp.2013.11.001
41. Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T, Wu J, Fu M, Wu ZH (2013) USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J 32:3206–3219. doi:10.1038/emboj.2013.247
42. Niu J, Wang K, Graham S, Azfer A, Kolattukudy PE (2011) MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-кB activation via inhibition of IкB kinase activation. J Mol Cell Cardiol 51:177–186. doi:10.1016/j.yjmcc.2011.04.018
43. Niu J, Wang K, Kolattukudy PE (2011) Cerium oxide nanoparticles inhibit oxidative stress and nuclear factor-κB activation in H9c2 cardiomyocytes exposed to cigarette smoke extract. J Pharmacol Exp Ther 338:53–61. doi:10.1124/jpet.111.179978
44. Niu J, Wang K, Zhelyabovska O, Saad Y, Kolattukudy PE (2013) MCP-1-induced protein promotes endothelial-like and angiogenic properties in human bone marrow monocytic cells. J Pharmacol Exp Ther 347:288–297. doi:10.1124/jpet.113.207316
45. Papait R, Greco C, Kunderfranco P, Latronico MV, Condorelli G (2013) Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol 108:361. doi:10.1007/s00395-013-0361-1
46. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP (2004) Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 35:2576–2581. doi:10.1161/01.STR.0000143450.04438.ae
47. Roy A, Zhang M, Saad Y, Kolattukudy PE (2013) Antidicer RNAse activity of monocyte chemotactic protein-induced protein-1 is critical for inducing angiogenesis. Am J Physiol Cell Physiol 305:C1021–C1032. doi:10.1152/ajpcell.00203.2013
48. Schroen B, Heymans S (2012) Small but smart–microRNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing. Cardiovasc Res 93:605–613. doi:10.1093/cvr/cvr268
49. Skalniak L, Mizgalska D, Zarebski A, Wyrzykowska P, Koj A, Jura J (2009) Regulatory feedback loop between NF-κB and MCP-1-induced protein 1 RNase. FEBS J 276:5892–5905. doi:10.1111/j.1742-4658.2009.07273.x
50. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, Wang YR, Qin YW, Yuan WJ, Jing Q (2010) MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 225:437–443. doi:10.1002/jcp.22217
51. Sreejit P, Kumar S, Verma RS (2008) An improved protocol for primary culture of cardiomyocyte from neonatal mice. In Vitro Cell Dev Biol Anim 44:45–50. doi:10.1007/s11626-007-9079-4
52. Suzuki HI, Arase M, Matsuyama H, Choi YL, Ueno T, Mano H, Sugimoto K, Miyazono K (2011) MCPIP1 ribonuclease antagonizes Dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol Cell 44:424–436. doi:10.1016/j.molcel.2011.09.012
53. Topkara VK, Mann DL (2011) Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 25:171–182. doi:10.1007/s10557-011-6289-5
54. Valen G, Yan ZQ, Hansson GK (2001) Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38:307–314. doi:10.1016/S0735-1097(01)01377-8
55. Valeur HS, Valen G (2009) Innate immunity and myocardial adaptation to ischemia. Basic Res Cardiol 104:22–32. doi:10.1007/s00395-008-0756-6
56. van de Vrie M, Heymans S, Schroen B (2011) MicroRNA involvement in immune activation during heart failure. Cardiovasc Drugs Ther 25:161–170. doi:10.1007/s10557-011-6291-y
57. Younce CW, Azfer A, Kolattukudy PE (2009) MCP-1 (monocyte chemotactic protein-1)-induced protein, a recently identified zinc finger protein, induces adipogenesis in 3T3-L1 pre-adipocytes without peroxisome proliferator-activated receptor gamma. J Biol Chem 284:27620–27628. doi:10.1074/jbc.M109.025320
58. Zhang XQ, Tang R, Li L, Szucsik A, Javan H, Saegusa N, Spitzer KW, Selzman CH (2013) Cardiomyocyte-specific p65 NF-κB deletion protects the injured heart by preservation of calcium handling. Am J Physiol Heart Circ Physiol 305:H1089–H1097. doi:10.1152/ajpheart.00067.2013
59. Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM, Younce C, Binkley PF, Kolattukudy PE (2006) Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 98:1177–1185. doi:10.1161/01.RES.0000220106.64661.71